The Kinetics of Anti-Drug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immuno-Mediated Disorders

Conclusions The present data suggest that most IFX-exposed patients develop ADA within the first year of treatment irrespective of disease type. The clinical outcome to the treatment is preceded by ADA development, which in turn, is aassociated with the reduction of drug serum levels. Both ADA evaluation, as well as therapeutic drug monitoring, may have a relevant impact on clinical practice, giving new insights to predict LOR and HR.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research